Tessa Romero
Stock Analyst at JP Morgan
(3.73)
# 706
Out of 4,855 analysts
60
Total ratings
44.44%
Success rate
10.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $26 → $30 | $21.98 | +36.49% | 7 | Jun 6, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Overweight | $16 → $10 | $3.88 | +157.73% | 2 | May 30, 2025 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $18 → $17 | $14.70 | +15.65% | 5 | Mar 21, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $72 → $68 | $17.03 | +299.30% | 6 | Mar 5, 2025 | |
| UPB Upstream Bio | Initiates: Overweight | $38 | $11.27 | +237.18% | 1 | Nov 5, 2024 | |
| NMRA Neumora Therapeutics | Downgrades: Neutral | $18 → $15 | $1.02 | +1,370.59% | 4 | Nov 5, 2024 | |
| MCRB Seres Therapeutics | Downgrades: Underweight | n/a | $8.23 | - | 2 | Oct 24, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $18 → $31 | $34.23 | -9.44% | 5 | Oct 14, 2024 | |
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $32.30 | +119.81% | 4 | Sep 5, 2024 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Overweight | $32 → $29 | $8.94 | +224.38% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $31 | $15.24 | +103.48% | 8 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $46 | $34.32 | +34.03% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $5.27 | +32.83% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $55 | $31.64 | +73.83% | 2 | Apr 25, 2023 |
ACADIA Pharmaceuticals
Jun 6, 2025
Maintains: Overweight
Price Target: $26 → $30
Current: $21.98
Upside: +36.49%
Lexeo Therapeutics
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $3.88
Upside: +157.73%
Dyne Therapeutics
Mar 21, 2025
Maintains: Neutral
Price Target: $18 → $17
Current: $14.70
Upside: +15.65%
Biohaven
Mar 5, 2025
Maintains: Overweight
Price Target: $72 → $68
Current: $17.03
Upside: +299.30%
Upstream Bio
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $11.27
Upside: +237.18%
Neumora Therapeutics
Nov 5, 2024
Downgrades: Neutral
Price Target: $18 → $15
Current: $1.02
Upside: +1,370.59%
Seres Therapeutics
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $8.23
Upside: -
Scholar Rock Holding
Oct 14, 2024
Maintains: Overweight
Price Target: $18 → $31
Current: $34.23
Upside: -9.44%
Cytokinetics
Sep 5, 2024
Maintains: Overweight
Price Target: $65 → $71
Current: $32.30
Upside: +119.81%
EyePoint Pharmaceuticals
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $8.94
Upside: +224.38%
Aug 12, 2024
Maintains: Overweight
Price Target: $30 → $31
Current: $15.24
Upside: +103.48%
Jun 13, 2024
Reinstates: Neutral
Price Target: $46
Current: $34.32
Upside: +34.03%
Aug 22, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $5.27
Upside: +32.83%
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $31.64
Upside: +73.83%